RxDoctor Payments Data

Mark Moran, MD

Interventional Cardiology · Medford, ORNPI 1023026622

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $496 and has fallen 74.5% since, to $127 in 2024. That places this record below the midpoint for interventional cardiology clinicians in OR, where the typical reported total is $4,729.

$1,380in general payments, 2019–2025

Across 52 payments — averaging $26.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$296
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$222
  • Abiomed$186
  • Philips North America LLC$171
  • Boston Scientific$131
  • Teleflex LLC$109
  • plus $264 from 6 others

What the payments were for

  • Food & beverage$1,36999%
  • Education$111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,380 in reported general payments places this provider in the 25th percentile of 68 interventional cardiology providers in Oregon.

See all interventional cardiology providers in Oregon

Medicare billing

Part B allowed, 2024
$145,758
Medicare patients
967
Services billed
2,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban257$313,241
EntrestoSacubitril/Valsartan100$103,886
XareltoRivaroxaban79$75,520
JardianceEmpagliflozin19$14,726
Metoprolol Succinate431$5,671
Digoxin71$3,334
Ezetimibe104$3,010
ClopidogrelClopidogrel Bisulfate174$2,734
Potassium Chloride119$2,721
Flecainide Acetate53$2,595
Rosuvastatin Calcium155$2,254
Amiodarone Hcl57$1,857
Losartan Potassium138$1,836
Atorvastatin Calcium169$1,575
Lisinopril141$1,507

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →